Adenosine A2A and Beta-2 Adrenergic Receptor Agonism: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Richard J. Rickles(The University of Texas at San Antonio Health Science Center), Margaret Lee(Boston University), Vikram Kansra(The University of Texas at San Antonio Health Science Center), Jennifer S. Carew(University of Arizona), Winnie F. Tam(The University of Texas at San Antonio Health Science Center), Francis J. Giles(National University of Ireland), Steffan T. Nawrocki(University of Arizona), David Crowe(The University of Texas at San Antonio Health Science Center), Melissa Farwell(The University of Texas at San Antonio Health Science Center), William Avery(The University of Texas at San Antonio Health Science Center), Mei Chen(Guangzhou Medical University), Thomas P. Giordano(Baylor College of Medicine), Laura Pierce(The University of Texas at San Antonio Health Science Center), Alexander Brown
Blood
November 16, 2008
10.1182/blood.v112.11.384.384
Cited by 4

Related Papers

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
|Blood|2006|691
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
|Cancer|2006|607
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance
|Blood|2007|485